ZARXIO Drug Profile

Summary for Tradename: ZARXIO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ZARXIO
Recent Clinical Trials:	See clinical trials for ZARXIO

See drug prices for ZARXIO

Recent Clinical Trials for ZARXIO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Massachusetts General Hospital	PHASE2
Stanford University	Phase 1/Phase 2
Rutgers, The State University of New Jersey	Early Phase 1

See all ZARXIO clinical trials

Pharmacology for ZARXIO

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZARXIO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZARXIO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZARXIO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for ZARXIO

Last updated: April 21, 2026

What is ZARXIO and its current market position?

ZARXIO (filgrastim-sndz) is a biosimilar to Neupogen (filgrastim), approved by the FDA in 2018. It is used to stimulate white blood cell production in patients undergoing chemotherapy, bone marrow transplants, or experiencing neutropenia. ZARXIO entered a competitive market dominated by originator biologics and other biosimilars.

Market size and growth drivers

• Global neutropenia treatment market was valued at approximately USD 4.2 billion in 2022.
• Expected to grow at a compound annual growth rate (CAGR) of 7% from 2023 to 2030 [1].

Key drivers include increased cancer incidence rates, expanding indications for growth stimulation, and policy shifts favoring biosimilars to contain healthcare costs.

Competitive landscape

Product	Market Share (2022)	Manufacturer	Approval Year	Price Advantage	Patent Status
Neupogen (originator)	60%	Amgen	1991	No	Patent expired in 2013 [2]
Zarxio (biosimilar to Neupogen)	35%	Sandoz (Novartis)	2015	Significant	Patent settled in 2013 [3]
Nivestym	5%	Pfizer	2019	Moderate	Patent status uncertain

Market shares fluctuate based on regional approvals, pricing strategies, and formulary inclusion. Biosimilar adoption lag varies by country; US uptake is slower compared to Europe.

Revenue and financial projections

• Estimated 2022 revenues for ZARXIO: USD 250 million, primarily in North America and Europe.
• CAGR forecast (2023-2030): 8%. This projection reflects increasing adoption amidst biosimilar price competition and expanding indications.

Year	Revenue (USD million)	Growth Rate
2022	250	—
2025	380	11% CAGR
2030	560	8% CAGR

Margins are expected to improve as manufacturing costs reduce with scale. Price erosion pressures remain due to biosimilar competition and payer policies.

Regulatory and policy impacts

• U.S. law allows biosimilar substitution at pharmacy level, accelerating market penetration.
• European Medicines Agency (EMA) approved multiple biosimilars, enhancing competition.
• Patent litigations historically delayed biosimilar market entry; newer regulations and settlement agreements have accelerated launches.

Market access and reimbursement trends

• Payers favor biosimilars for cost savings; some regions mandate substitution.
• Restricted formularies favor biosimilars like ZARXIO, supporting revenue expansion.
• Price negotiations and tender processes influence revenue trajectory.

Risks and challenges

• Patent litigations from originator (Amgen) can delay additional biosimilar launches.
• Physician and patient familiarity with brand-name drugs limits biosimilar uptake.
• Manufacturing capacity constraints could impact supply, influencing revenue potential.

Strategic considerations

• Differentiation through cost leadership and supply reliability.
• Expanding indications, e.g., rare neutropenia, to grow patient population.
• Enhancing market access by engaging payers and clinicians early.

Key takeaways

ZARXIO faces a mature yet growing biosimilar market driven by cost pressures and expanding indications. Revenue growth is steady, with projections reaching USD 560 million by 2030, contingent on competitive dynamics, regulatory landscapes, and market acceptance.

FAQs

1. How does ZARXIO compare price-wise to its originator?
ZARXIO is priced approximately 15-30% lower than Neupogen, depending on region, contributing to increased biosimilar adoption.

2. What regions represent the largest growth opportunities for ZARXIO?
North America and Europe remain primary markets, with emerging markets showing potential due to healthcare infrastructure improvements.

3. What regulatory challenges does ZARXIO face?
Patent litigations from Amgen can delay biosimilar entries; however, settlement agreements have mitigated some delays.

4. How has COVID-19 impacted biosimilar sales?
Disruptions in healthcare delivery temporarily slowed sales in 2020 but have rebounded as elective treatments resumed.

5. What are the prospects for new indications?
FDA approvals for additional uses, such as mobilization of peripheral blood stem cells, can expand market potential.

References

[1] Research and Markets. (2022). Global Neutropenia Treatment Market Report.
[2] U.S. Patent Office. (2013). Patent expiry of Neupogen.
[3] Amgen. (2013). Settlement agreement with Sandoz concerning Zarzio patent.